Abstracts tagged "risk assessment"

Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Melody Esmaeili¹, Linh Truong², Nicole Ridolfi³, Eugenia Chen⁴ and Maida wong⁵, ¹University of California, Irvine, Orange, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California, Irvine, Newport Beach, CA, ⁴Long Beach VA Hospital, Irvine, CA, ⁵Long Beach VA Hospital, Los Angeles, CA
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
Abstract Number: 0721 • ACR Convergence 2024
Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study
Xavier Puéchal¹, Michele Iudici¹, Elodie Perrodeau², Claire Goulvestre³, Pascal cohen⁴, Alexis Régent¹, Luc Mouthon⁵, Loïc Guillevin⁴, Raphael Porcher⁶ and Benjamin Terrier⁷, ¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²Hôtel-Dieu, Paris, France, ³Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a frequently relapsing disease for which a meta-analysis concluded that an increase or persistence of ANCA during remission is only…
Abstract Number: 1723 • ACR Convergence 2024
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Fabio Cacciapaglia¹, Vincenzo Venerito², Gian Luca Erre³, Matteo Piga⁴, Andreina Manfredi⁵, Garifallia Sakellariou⁶, Ombretta Viapiana⁷, Elisa Gremese⁸, Elena Bartoloni Bocci⁹, Francesca Romana Spinelli¹⁰ and Fabiola Atzeni¹¹, and "Cardiovascular Obesity and Rheumatic DISeases" Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit, DiMePRe-J University of Bari, Bari, Italy, ³Rheumatology Unit - University of Sassari, Sassari, Italy, ⁴Rheumatology Unit - University of Cagliari, Cagliari, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁷Rheumatology Unit, University of Verona, Verona, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹⁰Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹¹University of Messina, Italy, Messina, Italy
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased cardiovascular (CV) risk, but traditional CV risk factors and available 10-year CV risk estimation models may not…
Abstract Number: 2418 • ACR Convergence 2024
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Matthew Linnik¹, Guilherme Rocha², David Gemperline³, Ernst Dow³, Christoph Preuss³, Helen Masson⁴, Olivia Ellis⁴, Ana Accioly³, Maja Hojnik⁵, Kira Rubtsova¹, Robert Benschop⁶, Mark Chambers⁷, Mark Genovese³ and Richard Higgs³, ¹Eli Lilly, San Diego, CA, ²Eli Lilly, Indianapolis, IN, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly and Co, San Diego, CA, ⁵Eli Lilly and Co., Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Zionsville, IN
Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
Abstract Number: 0209 • ACR Convergence 2024
Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
Abstract Number: 0851 • ACR Convergence 2024
Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Lihi Eder¹, Ricardo Acayaba de Toledo², Fahmeen Afgani³, Catherine Bakewell⁴, Philippe Carron⁵, Basant Elnady⁶, Amir Haddad⁷, Arthur Kavanaugh⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, NZEUSSEU TOUKAP Adrien¹², Marcos Rosemffet¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Ágnes Sarolta Szentpétery¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Ilaria Tinazzi¹⁹, Janeth Yinh¹⁰, Gurjit Kaeley²⁰ and Sibel Aydin²¹, ¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ²FAMERP, São José do Rio Preto, Brazil, ³Women's College Hospital, Toronto, Canada, ⁴Intermountain Health Care, Salt Lake City, UT, ⁵UZ Gent, Gent, Belgium, ⁶Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, ⁷Carmel Medical Centre, Haifa, Israel, ⁸University of California San Diego, La Jolla, CA, ⁹GRAPPA - Patient Research Partner, Haifa, Israel, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Hospital Italiano de Buenos Aires, buenos aires, Argentina, ¹²Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ¹³Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁴Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, FL, ¹⁶Uppsala University Hospital, Uppsala, Sweden, ¹⁷University of California, San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²⁰UF COM-J, Ponte Vedra Beach, FL, ²¹University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…
Abstract Number: 1724 • ACR Convergence 2024
Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis
Tate Johnson¹, Halie Frideres², Punyasha Roul³, Yangyuna Yang¹, Joshua Baker⁴, Sauer brian⁵, grant Cannon⁶, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Existing cardiovascular disease (CVD) risk calculators have inadequately estimated CVD risk in people with rheumatoid arthritis (RA). The American Heart Association (AHA) recently developed…
Abstract Number: 2444 • ACR Convergence 2024
Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
Ryan Osgueritchian¹, Hoda Mombeini¹, Vivek Jani², Adrianne Woods³, Steven Hsu¹, Matthew Lammi⁴, Paul Hassoun⁴, Fredrick Wigley⁵, Laura Hummers⁶, Stephen Mathai⁷, Ami Shah⁸ and Monica Mukherjee¹, ¹Johns Hopkins University Division of Cardiology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷Johns Hopkins University Division of Pulmonary and Critical Care Medicine,, Blatimore, ⁸Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Pulmonary hypertension (PH) portends poor outcomes in Systemic Sclerosis (SSc). Recent efforts for early identification and intervention in SSc patients with pulmonary arterial hypertension…
Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 2469 • ACR Convergence 2024
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Stefano Di Donato¹, Vishal Kakkar², Silvia Bellando-Randone³, Marco Matucci-Cerinic⁴ and Francesco Del Galdo², and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 1000 • ACR Convergence 2024
Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Hafsah Nabi², Dorte Vendelbo Jensen³, Jens Pedersen⁴, Oliver Hendricks⁵, Anne Gitte Loft⁶, Ada Colic⁷, Kamilla Danebod³, Salome Kristensen⁸, Heidi Munk⁹, Niels Lomborg¹⁰, Natalia Manilo¹¹, Stavros Chrysidis¹², Søren Just¹³, Asta Linauskas¹⁴, Pil Højgaard¹⁵, Pia Høger Thygesen¹⁶, Malene Kildemand¹⁷, Rene Drage Oestgaard¹⁸, Merete Hetland¹⁹ and Bente Glintborg²⁰, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ⁵Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, ⁷Department of Rheumatology, Zealand University Hospital, Koege, Denmark, ⁸Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, ¹¹Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹²Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ¹³Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ¹⁴Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ¹⁵Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, ¹⁶Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁷Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, ¹⁸Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ²⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
Abstract Number: 1874 • ACR Convergence 2024
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Fabio Cacciapaglia¹, Gian Luca Erre², Matteo Piga³, Elena Bartoloni Bocci⁴, Andreina Manfredi⁵, Ennio Giulio Favalli⁶, Maria Sole Chimenti⁷, Serena Guiducci⁸, Eleonora Celletti⁹, Addolorata Corrado¹⁰, Alessandro Giollo¹¹, SIMONE PARISI¹², Ivan Giovannini¹³, Elisa Gremese¹⁴, Francesca Romana Spinelli¹⁵, Garifallia Sakellariou¹⁶, Ombretta Viapiana¹⁷ and Fabiola Atzeni¹⁸, and Cardiovascular Obesity and Rheumatic DISeases Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit - University of Sassari, Sassari, Italy, ³Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁴Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁷Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ⁸University of Florence, Pistoia, Italy, ⁹Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹⁰Rheumatology Unit, University of Foggia, Foggia, Italy, ¹¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ¹²Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁵Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ¹⁷Rheumatology Unit, University of Verona, Verona, Italy, ¹⁸University of Messina, Italy, Messina, Italy
Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].